| Synagis (palivizumab) / SOBI |
NCT01075178: Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease |
|
|
| Completed | N/A | 2036 | Europe | | Abbott | Severe Respiratory Syncytial Virus Infection | 01/10 | 01/10 | | |
INSPIRA, NCT01107535: Effectiveness of Synagis (Palivizumab) Immunoprophylaxis in Preterm Infants With High Risk of Severe Respiratory Syncytial Virus (RSV) Infection |
|
|
| Completed | N/A | 82 | RoW | Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice., palivizumab, Synagis | Abbott | Respiratory Syncytial Virus Infection | 02/11 | 02/11 | | |
NCT01297504: A One-Year Observation of Palivizumab in Infants at Risk for Respiratory Syncytial Virus Infection in Latin America |
|
|
| Completed | N/A | 464 | RoW | | AbbVie (prior sponsor, Abbott), Fundasamin (Argentina) | Respiratory Syncytial Virus Infection | 08/13 | 08/13 | | |
NCT01537198: Surveillance of Synagis in Korean Pediatric Patients |
|
|
| Completed | N/A | 618 | RoW | | AbbVie (prior sponsor, Abbott) | Respiratory Syncytial Virus Infection | 06/14 | 06/14 | | |
NCT02016690: Synagis® Liquid 50mg, 100mg for Intramuscular Injection Special Investigation in Immunocompromised Children With Synagis® |
|
|
| Completed | N/A | 312 | Japan | | AbbVie | Respiratory Syncytial Virus Infection | 12/15 | 12/15 | | |
NCT01155193: Prospective Study for the Use of Palivizumab (Synagis®) in High-risk Children in Germany |
|
|
| Completed | N/A | 30804 | NA | | AbbVie (prior sponsor, Abbott) | Respiratory Syncytial Virus Infections | 07/16 | 07/16 | | |
